The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
RETRACTED ARTICLE: MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials
Open accessAbstract
BACKGROUND: Posttraumatic stress disorder is a prevalent mental health condition with substantial impact on daily functioning that lacks sufficient treatment options. Here we evaluate six phase 2 trials in a pooled analysis to determine the study design for phase 3 trials of MDMA-assisted psychotherapy for PTSD. METHODS: Six randomized, double-blind, controlled clinical trials at five study sites were conducted from April 2004 to February 2017. Active doses of MDMA (75-125 mg, n = 72) or placebo/control doses (0-40 mg, n = 31) were administered to individuals with PTSD during manualized psychotherapy sessions in two or three 8-h sessions spaced a month apart. Three non-drug 90-min therapy sessions preceded the first MDMA exposure, and three to four followed each experimental session. RESULTS: After two blinded experimental sessions, the active group had significantly greater reductions in CAPS-IV total scores from baseline than the control group [MMRM estimated mean difference (SE) between groups - 22.0 (5.17), P < 0.001]. The between-group Cohen's d effect size was 0.8, indicating a large treatment effect. After two experimental sessions, more participants in the active group (54.2%) did not meet CAPS-IV PTSD diagnostic criteria than the control group (22.6%). Depression symptom improvement on the BDI-II was greatest for the active group compared to the control group, although only trended towards significant group differences [MMRM, estimated mean difference (SE) between groups - 6.0 (3.03), P = 0.053]. All doses of MDMA were well tolerated, with some expected reactions occurring at greater frequency for the active MDMA group during experimental sessions and the 7 days following. CONCLUSIONS: MDMA-assisted psychotherapy was efficacious and well tolerated in a large sample of adults with PTSD. These studies supported expansion into phase 3 trials and led to FDA granting Breakthrough Therapy designation for this promising treatment. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00090064, NCT00353938, NCT01958593, NCT01211405, NCT01689740, NCT01793610.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The effect sizes for improvements in PTSD and common co-occurring conditions in this pilot study were greater than those found with individually delivered MDMA-facilitated psychotherapy for PTSD (see Mithoefer et al., 2019 for pooled pre- to post-treatment effect in six phase 2 RCTs of approximately d = 1.20).”
From MDMA-facilitated cognitive-behavioural conjoint therapy for posttraumatic stress disorder: an uncontrolled trial (2020) · cites this paper as Mithoefer et al., 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MDMA-AT has also been most extensively tested in the treatment of post-traumatic stress disorder (PTSD) and has shown to result in large effect size differences compared to placebo controls in Phase II and Phase 3 trials (18–21).”
From MDMA-Assisted Therapy as a Means to Alter Affective, Cognitive, Behavioral, and Neurological Systems Underlying Social Dysfunction in Social Anxiety Disorder (2021) · cites this paper as [20]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“MDMA (3,4-methylenedioxymethamphetamine) has been used to facilitate an individual therapy for PTSD.”
From MDMA-facilitated cognitive-behavioural conjoint therapy for posttraumatic stress disorder: an uncontrolled trial (2020) · cites this paper as Mithoefer et al., 2019
The cited source says what the claim attributes to it.
In the citing paper
“In addition, both phase II (19) and the existing phase 3 study (20) suggest excellent safety and low abuse potential when MDMA is used under controlled conditions.”
In the citing paper
“Pooled analysis of six phase 2 trials of MDMA-assisted therapy for PTSD have now shown promising safety and efficacy findings15.”
From MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study (2021) · cites this paper as [15]
In the citing paper
“Although low-dose MDMA improved blinding in phase 2 studies, it led to decreased effectiveness compared with an inactive placebo in a PTSD population, making it easier to detect a difference between the active and comparator groups15.”
From MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study (2021) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients
Beck, A. T., Steer, R. A., Ball, R., & Ranieri, W. F. (1996) · Journal of Personality Assessment · doi:10.1207/s15327752jpa6703_13 · Cited by 5,965
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157
The development of a Clinician-Administered PTSD Scale
Blake, D. D., Weathers, F. W., Nagy, L. M., Kaloupek, D. G., Gusman, F. D., Charney, D. S., & Keane, T. M. (1995) · Journal of Traumatic Stress · doi:10.1002/jts.2490080106 · Cited by 5,024
Paced Auditory Serial-Addition Task: A Measure of Recovery from Concussion
Gronwall, D. M. A. (1977) · Perceptual and Motor Skills · doi:10.2466/pms.1977.44.2.367 · Cited by 2,395 · cited 2×
“Participants completed the PacedAuditory Serial Addition Task (PASAT) (Gronwall 1977) and Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) (Randolph 1998) at baseline and 2-month follow-up to determine whether changes in cognitive function had occurred after two sessions…”
MethodA Multidimensional Meta-Analysis of Psychotherapy for PTSD
Bradley, R., Greene, J., Russ, E., Dutra, L., & Westen, D. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.2.214 · Cited by 1,938
Kilpatrick, D. G., Resnick, H. S., Milanak, M. E., Miller, M. W., Keyes, K. M., & Friedman, M. J. (2013) · Journal of Traumatic Stress · doi:10.1002/jts.21848 · Cited by 1,929
Clinician-administered PTSD scale: A review of the first ten years of research
Weathers, F. W., Keane, T. M., & Davidson, J. R. T. (2001) · Depression and Anxiety · doi:10.1002/da.1029 · Cited by 1,903
Posttraumatic stress disorder in the world mental health surveys
Koenen, K. C., Ratanatharathorn, A., Ng, L., McLaughlin, K. A., Bromet, E. J., Stein, D. J., Karam, E. G., Meron Ruscio, A., Benjet, C., Scott, K., et al. (2017) · Psychological Medicine · doi:10.1017/s0033291717000708 · Cited by 1,453
(2007) · Medical Entomology and Zoology · Cited by 1,118
Prolonged Exposure Therapy for PTSD: Therapist Guide: Emotional processing of traumatic experiences
Foa, E. B., Hembree, E., & Rothbaum, B. (2007) · doi:10.1093/med:psych/9780195308501.001.0001 · Cited by 1,050
Research works printed but not linked: 2
- Grof S (2001) LSD psychotherapy, 4th edn. Multidisciplinary Association for Psychedelic Studies, Ben Lomond, CA
- Kadel R & Kip K (2012). A SAS macro to compute effect size (Cohen’s d) and its confidence interval from raw survey data. In Proceedings of the Annual Southeast SAS Users Group Conference
Cited by
Sorted by citations
Items 201–300 of 359
The historical opposition to psychedelic research and implications for credibility in psychiatry
Koning, E., Chu, E. M.-Y., & Brietzke, E. M. (2024) · CNS Spectrums · doi:10.1017/s1092852924002141 · Cited by 9
MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study
Kvam, T.-M., Goksøyr, I. W., Rog, J., van de Vooren, I.-T. J., Stewart, L. H., Autran, I., Berthold‐Losleben, M., Mørch-Johnsen, L. E., Holst, R., Clausen, I., et al. (2025) · The British Journal of Psychiatry · doi:10.1192/bjp.2025.10320 · Cited by 9
Makunts, T., Dahill, D., Jerome, L., de Boer, A., & Abagyan, R. A. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1149766 · Cited by 7
Therapeutic Use of Hallucinogens
Wiltenburg, V. D., Prado, D. D. R., & Mendes, F. (2021) · Springer eBooks · doi:10.1007/978-3-030-62855-0_35 · Cited by 1
Ethical considerations for psychedelic-assisted therapy in military clinical settings
Hoener, S., Wolfgang, A. S., Nissan, D. A., & Howe, E. G. (2023) · Journal of Medical Ethics · doi:10.1136/jme-2023-108943 · Cited by 8
Haye, W. D. L., Walcott, G. O., Eaton, J., Beckford, J., & Greene, J. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1136990 · Cited by 7
Can research on entactogens contribute to a deeper understanding of human sexuality?
Holka-Pokorska, J. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00552-7 · Cited by 6
Associations between MDMA/ecstasy use and physical health in a U.S. population-based survey sample
Jones, G. M., Ricard, J. A., Hendricks, P. S., & Simonsson, O. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221127318 · Cited by 7
Miranda, P., Castro, A., Díaz, P., Minini, L., Ferraro, F., Paulsen, E., Faccio, R., & Pardo, H. (2024) · Polymers · doi:10.3390/polym16152148 · Cited by 6
Race and Gender Differences in the Moderating Relationship of Psychedelics on Stigma and Distress
Viña, S. M. (2025) · Psychedelic Medicine · doi:10.1089/psymed.2024.0021 · Cited by 6
Baldo, B. A. (2024) · Archives of Toxicology · doi:10.1007/s00204-024-03765-8 · Cited by 6
Religious Social Integration, Psychedelics, and Psychological Distress
Viña, S. M. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2425021 · Cited by 6
O’Brien, S., & Nutt, D. (2025) · Cambridge University Press eBooks · doi:10.1017/9781009585330.008 · Cited by 7
The Overview Effect and Well-Being
Nezami, A., Persaud, L. M., & White, F. L. (2021) · Astrophysics and space science proceedings · doi:10.1007/978-3-030-70482-7_10 · Cited by 7
López‐Arnau, R., Camarasa, J., Carbó, M., Nadal‐Gratacós, N., Puigseslloses, P., Espinosa‐Velasco, M., Urquizu, E., Escubedo, E., & Pubill, D. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.990405 · Cited by 6
MDMA for the treatment of misophonia, a proposal
Webb, J., & Keane, S. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.983285 · Cited by 7
User perceptions of long-term costs and benefits of MDMA use: findings from a large online sample
Elsey, J. W. B., Wuestman, V. A. F., & Fieten, A. (2023) · Drugs Education Prevention and Policy · doi:10.1080/09687637.2023.2284643 · Cited by 6
Berquist, M. D., Leth‐Petersen, S., Kristensen, J. L., & Fantegrossi, W. E. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.107850 · Cited by 6
Luoma, J. B., Davis, A. K., Watts, R., & McCracken, L. M. (2020) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2020.01.004 · Cited by 6
Treatment resistant depression
Vaccarino, S. R., & Kennedy, S. H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821033-8.00003-4 · Cited by 7
The Psychedelic Renaissance: A Catholic Perspective
Carroll, T. (2024) · The Linacre Quarterly · doi:10.1177/00243639241274818 · Cited by 5
Argento, E., Goldenberg, S. M., Deering, K., Lavalley, J., Braschel, M. C., Bingham, B., & Shannon, K. (2022) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2022.100044 · Cited by 6
Using Psychedelics in Clinical Practice: Comparing Therapeutic Uses and Potential Harms
Tariq, R. (2022) · Current Clinical Pharmacology · doi:10.2174/2772432817666220321142707 · Cited by 5
Bhatt, S. R., Armstrong, M., Parker, T., Maviglia, M. A., Kass, R., Leeman, L. M., Romo, P., & Ziedonis, D. M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.905753 · Cited by 8
Methylenedioxymethamphetamine (MDMA)-Assisted Therapy in Hawaii: A Brief Review
Inouye, A. M., & Wolfgang, A. S. (2022) · Cureus · doi:10.7759/cureus.26402 · Cited by 5
Passie, T. (2023) · doi:10.1093/oso/9780198867364.001.0001 · Cited by 5
Psychedelic-Assisted Therapy for Social Adaptability in Autistic Adults
Danforth, A. L. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_269 · Cited by 5
Koolen, M. H. B., Wirsching, A., Krediet, E., & van Elk, M. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2508156 · Cited by 4
MDMA-Assisted Psychotherapy for PTSD: A Systematic Review of Randomized Control Trials
Brett, B. A., & Bynum, C. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2577308 · Cited by 4
Kvam, T.-M., Goksøyr, I. W., Rog, J., van de Vooren, I.-T. J., Stewart, L. H., Autran, I., Berthold‐Losleben, M., Mørch-Johnsen, L. E., Holst, R., Røssberg, J. I., et al. (2025) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.11.030 · Cited by 4
Mystical Love: The Universal Solvent
Laughlin, C. D., & Takahashi, M. (2020) · Anthropology of Consciousness · doi:10.1111/anoc.12120 · Cited by 4
Barnett, B. S., & Doblin, R. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1847365 · Cited by 7
Viña, S. M. (2025) · Drug Science Policy and Law · doi:10.1177/20503245251337357 · Cited by 4
Farré, M., Papaseit, E., Fonseca, F., & Torrens, M. (2020) · Springer eBooks · doi:10.1007/978-3-030-36391-8_19 · Cited by 5
MDMA – hopes and fears associated with therapeutic use in mental disorders
Kozera, K., Cichoń, L., Wilczyński, K. M., & Janas-Kozik, M. H. (2020) · Pharmacotherapy in Psychiatry and Neurology · doi:10.33450/fpn.2020.10.002 · Cited by 4
Žuljević, M. F., Viđak, M., Vukojević, J., Hren, D., & Peričić, T. P. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015345 · Cited by 5
Lee, Y., Chang, Y., Chi, Y.-C., Shelley, M., & Arndt, S. V. (2024) · Journal of Substance Use · doi:10.1080/14659891.2024.2323090 · Cited by 4
Green, W. M., Raut, S. B., James, F., Benedek, D. M., Ursano, R. J., & Johnson, L. R. (2023) · medRxiv · doi:10.1101/2023.08.17.23293955 · Cited by 4
Simon, G., Tadmor, N., & Halperin, D. (2025) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2025.105074 · Cited by 3
Dodds, C., Dawson, R. L., Lim, A., Tye, S. J., & Nasrallah, F. A. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251396255 · Cited by 4
Ramaekers, J. G., Kuypers, K. P. C., & Vollenweider, F. X. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03602-7 · Cited by 3
Fauvel, B., & Piolino, P. (2021) · Psychologie Française · doi:10.1016/j.psfr.2020.12.003 · Cited by 4
Anxiety-related Symptoms following the Sporadic Use of Ecstasy – A Case Study
Majić, T., Brandt, L., & Montag, C. (2021) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2021.2006372 · Cited by 3
Murray, H., Wild, J., & Ehlers, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818697-8.00229-6 · Cited by 3
Wright, D. J., Colagiuri, B., & Glozier, N. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-060360 · Cited by 4
Psychedelics for Use and Wellbeing Cultural Context and Recent Developments: A Jamaican Perspective
Haye, W. D. L. (2022) · Online Journal of Complementary & Alternative Medicine · doi:10.33552/ojcam.2022.08.000676 · Cited by 3
A reinforcement learning model with choice traces for a progressive ratio schedule
Ihara, K., Shikano, Y., Kato, S., Yagishita, S., Tanaka, K. F., & Takata, N. (2024) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2023.1302842 · Cited by 2
Licit use of illicit drugs for treating depression: the pill and the process
Pacheco, A. T., & Moghaddam, B. (2024) · Journal of Clinical Investigation · doi:10.1172/jci180217 · Cited by 3
Makunts, T., & Abagyan, R. A. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1414622 · Cited by 3
Cuttler, C., Stueber, A., Simone, J. J., & Mayo, L. M. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2452226 · Cited by 3
Stimulants: Definition, Pharmacology, Indications, Side Effects, and Treatment Strategies
Steinbuchel, P. H., & Greenhill, L. L. (2020) · Springer eBooks · doi:10.1007/978-3-319-56015-1_324-1 · Cited by 4
Serotonergic psychedelics for depression: A comprehensive overview
Wingert, A. M., Agnorelli, C., Peill, J., Reed, S., Nutt, D. J., & Erritzoe, D. (2025) · International Review of Neurobiology · doi:10.1016/bs.irn.2025.04.009 · Cited by 3
Psychedelics and cognitive function: A systematic review
Cardoso, C. G., & Viana, M. D. B. (2023) · Research Society and Development · doi:10.33448/rsd-v12i14.44436 · Cited by 2
Post-traumatic stress disorder in psychedelic research
Bostoen, T., Tap, S. C., Breeksema, J. J., & Schoevers, R. A. (2025) · International review of neurobiology · doi:10.1016/bs.irn.2025.02.004 · Cited by 2
Persistent Tinnitus after Inhaled N,N-dimethyltryptamine (DMT)
Diab, H., & Malcolm, B. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1847366 · Cited by 2
Jones, G. M., Lipson, J., & Wang, E. (2023) · Scientific Reports · doi:10.1038/s41598-023-29763-x · Cited by 3
Chasing the Numinous: Hungry Ghosts in the Shadow of the Psychedelic Renaissance
Osterhold, H. M., & Fernandes‐Osterhold, G. (2023) · Journal of Analytical Psychology · doi:10.1111/1468-5922.12949 · Cited by 4
Kratina, S., & Mayo, L. M. (2023) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2023.2246637 · Cited by 2
Is there a place for psychedelics in sports practice?
Portes, M. A. M., Werle, I., & Bertoglio, L. J. (2025) · Acta Neuropsychiatrica · doi:10.1017/neu.2025.13 · Cited by 3
Bioproduction of 3,4-methylenedioxymethamphetamine and derivatives
Özber, N., Li, J., & Facchini, P. J. (2025) · BioDesign Research · doi:10.1016/j.bidere.2025.100011 · Cited by 2
Pharmacological assistance for psychotherapy
Lochtenberg, J., Kirshenbaum, A. P., & Johnson, M. W. (2021) · Emerging Trends in Drugs Addictions and Health · doi:10.1016/j.etdah.2021.100017 · Cited by 2
Hallucinogen-Related Disorders
Kim, K. K., & Roberts, D. E. (2021) · Psychiatry update · doi:10.1007/978-3-030-86430-9_5 · Cited by 2
Passie, T. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198867364.003.0006 · Cited by 2
Post-traumatic Stress Disorder in Middle Age and Beyond
Marshall, L. L., & Hayslett, R. L. (2021) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2021.191 · Cited by 2
Hopper, J. W. (2020) · Journal of Trauma & Dissociation · doi:10.1080/15299732.2020.1718968 · Cited by 2
Filippo, R. D. (2021) · DZNE Pub · doi:10.6084/m9.figshare.14229545 · Cited by 2
Ching, T. H. W. (2020) · OpenCommons - UConn (University of Connecticut) · Cited by 2
MDMA-assisted therapy for borderline personality disorder
Inouye, A. M., Wolfgang, A. S., & Philhower, L. T. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00196 · Cited by 1
Passie, T. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198867364.003.0012 · Cited by 1
Inouye, A. M., Wolfgang, A. S., & Philhower, L. T. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00281 · Cited by 1
Qualitative Analysis of Views of Psychedelic-Assisted Therapy in Low-Income, Urban, Black Americans
Carter, S. E., Packard, G. A., & Maples‐Keller, J. L. (2025) · Psychedelic Medicine · doi:10.1089/psymed.2024.0015 · Cited by 1
Social Worker Attitudes towards Psychedelics
Nowakowski-Sims, E., & Holzworth, J. (2025) · Clinical Social Work Journal · doi:10.1007/s10615-025-00988-9 · Cited by 2
Kronman, H. G., Locker, A., Assadi, A., & Guss, J. R. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2025.00402 · Cited by 1
Pagano, L. A., & Pagano, T. P. (2025) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-025-00367-8 · Cited by 1
Unequal Healing: Gender, Psychedelics, and the Burden of Care
Viña, S. M. (2026) · Women & Therapy · doi:10.1080/02703149.2026.2615886 · Cited by 1
Effect of app-based mindfulness on extinction recall – a 7T-fMRI study
Björkstrand, J., Olsson, E., Clancy, O., Möller, S., Björkman-Burtscher, I. M., Raheja, N., Sjöström, D., Persiani, M. T. L., Staiano, W., & Kirk, U. (2026) · Scientific Reports · doi:10.1038/s41598-026-45569-z · Cited by 1
Evidence in practice: implementing KAT in indigenous health services
Lovely, J. J., Yardley, H., Darda, R., Adolpho, Q., Kemp, L., Brough, C., Doore, V., Kohlhammer, J., & Charrette, A. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1722573 · Cited by 1
Hammel, R. L., Gulliver, B. J., Sukich, S. N., & Abraham, S. (2022) · International Journal of Science and Research Methodology · doi:10.25166/ijsrm/2022.20.3.2 · Cited by 1
Novel Mechanisms and Interventions for PTSD
(2023) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.23021010 · Cited by 1
Passie, T. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198867364.003.0004 · Cited by 1
Passie, T. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198867364.003.0008 · Cited by 1
Passie, T. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198867364.003.0010 · Cited by 1
Medical Use of Cannabinoids and Psychedelic Compounds
Inserra, A., Gregorio, D. D., & Gobbi, G. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_141-1 · Cited by 1
Pharmacological, Somatic, and Behavioral Augmentations of PE
Bird, C. M., Douglas, M. E., & Powers, M. B. (2024) · CBT: science into practice · doi:10.1007/978-3-031-72720-7_11 · Cited by 1
Swank, M. (2020) · International Journal of Jungian Studies · doi:10.1163/19409060-bja10006 · Cited by 3
Kang, M., Mackay, L., Christie, D., Callon, C., & Argento, E. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00190 · Cited by 1
Drug and MDMA Interactions Implications for Public Health
Papaseit, E., Farré, M., & Pérez‐Mañá, C. (2022) · Springer eBooks · doi:10.1007/978-3-030-92392-1_121 · Cited by 1
7450 Summit Cir, D., & Naher, S. (2023) · Journal of Sociology Psychology & Religious Studies · doi:10.53819/81018102t4217 · Cited by 1
Are Psychedelics Something New in Teaching Psychopharmacology?
Louie, A. K., Beresin, E. V., Coverdale, J., Balon, R., Guerrero, A. P. S., Morreale, M. K., Aggarwal, R., & Brenner, A. M. (2020) · Academic Psychiatry · doi:10.1007/s40596-020-01294-x · Cited by 1
Journey To The Centre Of The Mind: Psychedelic Treatment of Mental Health in Aotearoa
Lutyens, D. (2023) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.21904854 · Cited by 2
An Alternative Approach in the Treatment of Anxiety Disorders: Current DirectionsPreprint
Antos, Z., Zackiewicz, K., Tomaszek, N., Modzelewski, S., & Waszkiewicz, N. (2024) · Preprints.org · doi:10.20944/preprints202406.1166.v1 · Cited by 1
Bailey, C. (2020) · BJPsych Bulletin · doi:10.1192/bjb.2020.26
Hallucinogens as Therapeutic Agents: Past, Present, and Future
Vos, E., Snelders, S., & Pieters, T. (2020) · Springer eBooks · doi:10.1007/978-3-319-56015-1_425-1
Klassische und neue Substanzen auf dem Prüfstand
Häckel, A. (2021) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-021-1897-5
The PACT Model: Improving Outcomes in the Treatment of PTSD
Larova, V., & Frederick, H. (2021) · Journal of Humanistic Psychology · doi:10.1177/00221678211009993
Colligan, S., Engle, Z., & Gawrysiak, M. J. (2021)
Integrative Psychiatry and Brain Health
Sauls, T. (2021) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2021.06.011
Ethnography Of A Novel Remote Use Of An MDA CeremonyPreprint
Ferenstein, G. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3911335
Kloft, L. (2021) · Research Publications (Maastricht University) · doi:10.26481/dis.20210623lk
Cabrera, J., & Marsh, A. N. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-818954-2.00017-1
Metadata
- Authors
- Mithoefer, M. C., Feduccia, A. A., Jerome, L., Mithoefer, A., Wagner, M., Walsh, Z., Hamilton, S., Yazar-Klosinski, B., Emerson, A., & Doblin, R.
- Affiliations
- Medical University of South Carolina (US)
- Multidisciplinary Association for Psychedelic Studies (US)
- University of British Columbia, Okanagan Campus (CA)
- Stanford Medicine (US)
- Corresponding author
- Feduccia, Allison A.
- Venue
- Psychopharmacology
- Published
- 2019-05-07
- Volume
- 236
- Issue
- 9
- Pages
- 2735-2745
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- PMC
- PMC6695343
- OpenAlex
- W2944263526
- Cited by
- 359
- References
- 39
- Citations by year
- 2026: 14 · 2025: 32 · 2024: 54 · 2023: 76 · 2022: 78 · 2021: 56 · 2020: 38 · 2019: 11
- FWCI
- 53.72
- Type
- journal article
- Language
- en
- Status
- Retracted
- Update notices
- retraction (2024-08-10)
- Open access
- hybrid
- doi.org
- Locations
- Psychopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Multidisciplinary Association for Psychedelic Studies (X)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- MDMA-assisted psychotherapy, MDMA, post-traumatic stress disorder, phase 3 trial design, treatment efficacy, depression symptom improvement, tolerability, breakthrough therapy designation
- MeSH terms
- Adult, Combined Modality Therapy, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Middle Aged, Psychotherapy, Stress Disorders, Post-Traumatic, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, Clinical Trials, Phase III as Topic, Serotonin Agents, N-Methyl-3,4-methylenedioxyamphetamine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review